Evidence map›Paper›PMID 32367297›Full record

ArticleJournal of neurology2020

Familial Creutzfeldt-Jakob disease homozygous to the E200K mutation: clinical characteristics and disease course.

Zeev Nitsan, Oren S Cohen, Joab Chapman, Esther Kahana, Amos D Korczyn, Shmuel Appel, Michael Osherov, Hanna Rosenmann, Ron Milo

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Hypothesis: functional age and onset of autosomal dominant genetic prion disease.Theory in biosciences = Theorie in den Biowissenschaften · 2023
    Article
  3. Prion Mutations in Republic of Republic of Korea, China, and Japan.International journal of molecular sciences · 2022
    Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Zeev NitsanDepartment of Neurology, Barzilai University Medical Center, 2 Hahistadrut St., 7830604, Ashkelon, Israel. zeevn@bmc.gov.il.
Oren S CohenDepartment of Neurology, Assaf Harofeh Medical Center, Zerifin, Israel.
Joab ChapmanDepartment of Neurology, The Sagol Neuroscience Center, Chaim Sheba Medical Center, Ramat Gan, Israel.
Esther KahanaDepartment of Neurology, Barzilai University Medical Center, 2 Hahistadrut St., 7830604, Ashkelon, Israel.
Amos D KorczynSackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Shmuel AppelDepartment of Neurology, Barzilai University Medical Center, 2 Hahistadrut St., 7830604, Ashkelon, Israel.
Michael OsherovDepartment of Neurology, Barzilai University Medical Center, 2 Hahistadrut St., 7830604, Ashkelon, Israel.
Hanna RosenmannDepartment of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Ron MiloDepartment of Neurology, Barzilai University Medical Center, 2 Hahistadrut St., 7830604, Ashkelon, Israel.
Ben-Gurion University of the Negev · ILBarzilai Medical Center · ILTel Aviv University · ILHadassah Medical Center · ILSheba Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo characterize the demographic, clinical features and disease course of familial Creutzfeldt-Jakob disease (fCJD) patients homozygous to the E200K mutation.

methodsThe Israeli National CJD Database was screened for patients homozygous to the E200K mutation. Patients' demographic data, clinical presentation and neurological findings, tau protein levels in the cerebrospinal fluid (CSF) and EEG, were assessed.

resultsTen homozygous E200K patients were identified (80% males). Average age of onset was 47.5 ± 6.1 years (range 40-56) and the average age of death was 49.3 ± 7. 7 years (range 42-63) with average disease duration of 27.7 ± 9.7 months (range 2-97). Initial clinical presentation included behavioral change in 4/10 patients, cognitive decline in 3/10 patients and focal neurological deficits in 2/10 patients. Throughout the disease course, the clinical signs in descending order of prevalence included cerebellar (70%), brainstem (60%), extrapyramidal (50%), pyramidal (50%), frontal lobe signs (30%), and disturbances of ocular motility (30%) Compared to the 228 heterozygous E200K fCJD patients, the 10 homozygous patients were significantly younger at disease onset (47.5 vs 59.7 years, p < 0.001), had a longer disease duration (27.7 vs 8.5 months, p < 0.001) and presented more frequently with behavioral changes as initial manifestation (4/10 vs. 34/228, p = 0.05).

conclusionsHomozygous E200K fCJD patients are characterized by a relatively younger age of onset and longer disease duration. Behavioral changes as a presenting symptom were more common in homozygous patients and cerebellar dysfunction was the most common neurological manifestation throughout the disease course.

Indexed as

Creutzfeldt-Jakob SyndromeAdultDisease ProgressionFemaleHomozygoteHumansMaleMiddle AgedMutationCreutzfeldt–Jakob diseaseE200KFamilialGeneticsHeterozygousHomozygousPrion

Identifiers

PMID32367297
OpenAlexW3021924497

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.